| Autor: |
Salame MY; The Andreas Gruentzig Cardiovascular Center, Department of Interventional Cardiology Emory University Hospital, Atlanta, USA, 2St Mary's Hospital, Portsmouth, UK., More RS, Verheye S, Leimbach ME, King SB III, Chronos NA |
| Jazyk: |
angličtina |
| Zdroj: |
International journal of cardiovascular interventions [Int J Cardiovasc Intervent] 1999; Vol. 2 (4), pp. 207-215. |
| DOI: |
10.1080/acc.2.4.207.215 |
| Abstrakt: |
Glycoprotein IIb/IIIa receptor inhibitors represent a relatively new therapeutic approach in the field of antiplatelet therapy. Following the development of abciximab a number of small molecule GPIIb/IIIa inhibitors have been introduced such as tirofiban and eptifibatide. In this fast-moving field the interventional cardiologist needs a framework to guide decision-making for the individual patient. This review covers the efficacy and safety data from the clinical trials of GPIIb/IIIa inhibitors in the context of patients undergoing percutaneous coronary intervention for unstable angina/non-Q-wave myocardial infarction. There is an increasing body of evidence to support the efficacy of GPIIb/IIIa inhibitors in reducing the risk of adverse ischemic events in high and low risk patients undergoing percutaneous coronary intervention. A number of unresolved efficacy and safety issues remain, including the duration of treatment before and after intervention; whether a reduction in the heparin dose would further decrease the risk of hemorrhage without affecting the periprocedural thrombotic rate in patients undergoing PTCA with adjunctive GPIIb/IIIa inhibitors; and the cost-effectiveness of this therapy. When a thorough analysis of cost-effectiveness has been made, it will be easier to advocate the widespread use of these agents in all patients undergoing coronary intervention. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
